Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: Journal of Medical Internet Research

Date Submitted: Aug 21, 2020
Date Accepted: Mar 4, 2021
Date Submitted to PubMed: Mar 17, 2021

The final, peer-reviewed published version of this preprint can be found here:

Acceptance of Telerheumatology by Rheumatologists and General Practitioners in Germany: Nationwide Cross-sectional Survey Study

Muehlensiepen F, Knitza J, Marquardt W, Engler J, Hueber A, Welcker M

Acceptance of Telerheumatology by Rheumatologists and General Practitioners in Germany: Nationwide Cross-sectional Survey Study

J Med Internet Res 2021;23(3):e23742

DOI: 10.2196/23742

PMID: 33690147

PMCID: 8042540

Acceptance of Telerheumatology: Results of a nationwide Survey of Rheumatologists and General Practitioners

  • Felix Muehlensiepen; 
  • Johannes Knitza; 
  • Wenke Marquardt; 
  • Jennifer Engler; 
  • Axel Hueber; 
  • Martin Welcker

ABSTRACT

Background:

The worldwide burden of musculoskeletal diseases is increasing. The number of newly registered rheumatologists has stagnated. Primary care, which takes up a key role in early detection of rheumatic disease is working at full capacity. COVID-19 and its containment impede rheumatological treatment. Telemedicine in rheumatology (telerheumatology) could support rheumatologists and general practitioners.

Objective:

To investigate acceptance and preferences related to the use of telerheumatology care among German rheumatologists and general practitioners.

Methods:

A nationwide cross-sectional, self-completed, paper-based survey on telemedicine in rheumatology care was conducted among outpatient rheumatologists and general practitioners (pre-COVID-19).

Results:

A total of 73% (349/476) of survey participants rated their knowledge of telemedicine as unsatisfactory, poor, or very poor. The majority of survey participants (358/480, 75%) answered that they do not currently use telemedicine, although 62% would like to (291/467). Barriers to the implementation of telemedicine include the purchase of technology equipment (182/292, 62%), administration (181/292, 62%) and poor reimbursement (156/292, 53%). Seventy percent (117/168) of the surveyed physicians reckoned telemedicine could be used in rheumatology. Surveyed physicians would prefer to use telemedicine to communicate directly with other physicians (370/455, 81%), than to communicate with patients (213/455, 47%). Among treatment phases, 64% of participants would choose to use telemedicine during ‘follow-up’ (291/452). Half of the participants would choose 'telecounseling' as a specific approach to improve rheumatology care (91/170, 54%).

Conclusions:

Before COVID-19 appeared, our results indicated generally low use but high acceptance of the implementation of telerheumatology among physicians. Participants indicated that the lack of a structural framework was a barrier to the effective implementation of telerheumatology. Training courses should be introduced to address the limited knowledge of physicians in the use of telemedicine. More research into telerheumatology is required. This includes large scale RCTs, economic analyses and the exploration of the user preferences.


 Citation

Please cite as:

Muehlensiepen F, Knitza J, Marquardt W, Engler J, Hueber A, Welcker M

Acceptance of Telerheumatology by Rheumatologists and General Practitioners in Germany: Nationwide Cross-sectional Survey Study

J Med Internet Res 2021;23(3):e23742

DOI: 10.2196/23742

PMID: 33690147

PMCID: 8042540

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.